Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Discussion - Public policy

5586 - Changing landscape of clinical cancer trials in Germany

Date

29 Sep 2019

Session

Poster Discussion - Public policy

Presenters

Susen Burock

Citation

Annals of Oncology (2019) 30 (suppl_5): v671-v682. 10.1093/annonc/mdz263

Authors

S. Burock1, T. Füreder2, S. Schauer1, U. Keilholz1

Author affiliations

  • 1 Charité Comprehensive Cancer Center, Charité - Universitätsmedizin Berlin, 10117 - Berlin/DE
  • 2 Internal Medicine I, Vienna General Hospital (AKH) - Medizinische Universität Wien, 1090 - Vienna/AT

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 5586

Background

The development of new therapeutic options for cancer patients due to a better understanding of tumor biology has profound effects on the design and conduct of modern clinical cancer research especially with respect to clinical trial design. Until recently, cancer drugs have been investigated in clinical trials for a definitive histological tumor type but this approach is slowly changing and recently drugs have been approved rather histology agnostic based on genomic alterations in various histological tumor types. Here we investigated the changes in the landscape of clinical cancer trials in Germany from 2000-2016.

Methods

Clinical trials gov database was queried in 2017 for interventional clinical cancer trials running in Germany with study start between 01/01/2000 and 31/12/2016. Data extracted from the database included the conditions, interventions, study phase, Sponsor/Collaborators, funder type, study design, outcome measures and number enrolled.

Results

Overall, 2977 trials matching the criteria were extracted. Number of studies heavily increased within the first decade from 32 studies in 2000 to 214 studies in 2010, remained thereafter relatively stable (with 260 in 2011, 243 in 2012, 236 in 2013, 252 in 2014, 274 in 2015 to 224 in 2016). There was a clear change in the study design over the years towards more trials with a placebo. Furthermore, the number of entities investigated within one clinical trial (from 1 tumor entity, 2-5 tumor entities, 6-10 tumor entities and >10 tumor entities (including clinical trials targeting events from various entities) increased over the years. With respect to sponsorship, there was an increase of industry-alone sponsorship over the years.Table: 1638PD

2000 - 20042005 - 20092010 - 20142015 - 2016
Masking
open label78%75%73%77%
single blind1%3%3%4%
double blind12%20%18%12%
quadruple1%2%6%6%
Missing9%0%0%1%
Placebo
Placebo - no95%82%80%85%
Placebo - yes5%18%20%15%
Number of entities
188%91%89%85%
2 - 56%3%4%5%
6 - 100%0%0%1%
> 106%5%7%10%
Sponsorship
Industrie alone43%68%65%64%
other57%32%35%36%

Conclusions

Cancer clinical trials have changed with respect to trial design and sponsorship during the last decade to cope with recent development of new cancer therapeutics.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Charité Universitätsmedizin Berlin.

Funding

Has not received any funding.

Disclosure

T. Füreder: Honoraria (self), Honoraria (institution), Research grant / Funding (institution): Norvartis; Honoraria (self), Honoraria (institution), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: BMS; Honoraria (self), Honoraria (institution), Advisory / Consultancy, Research grant / Funding (self), Research grant / Funding (institution), Travel / Accommodation / Expenses: MSD; Honoraria (self), Honoraria (institution), Advisory / Consultancy, Research grant / Funding (self), Research grant / Funding (institution): Merck Darmstadt; Honoraria (self), Honoraria (institution), Research grant / Funding (institution): AstraZeneca; Honoraria (self), Honoraria (institution), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Roche; Honoraria (self), Honoraria (institution), Advisory / Consultancy, Research grant / Funding (institution): Boehringer Ingelheim; Honoraria (self), Honoraria (institution), Advisory / Consultancy, Research grant / Funding (institution): Pfizer; Honoraria (self), Honoraria (institution), Research grant / Funding (institution): Sanofi; Honoraria (self), Honoraria (institution), Research grant / Funding (institution): Accord; Honoraria (institution), Research grant / Funding (institution): Celegene; Honoraria (institution), Research grant / Funding (institution): Ipsen; Honoraria (institution), Research grant / Funding (institution): Astellas; Non-remunerated activity/ies: President elect Austrian Head and Neck cancer society; Full / Part-time employment: Medical University of Vienna; Honoraria (institution): Johnson and Johnson ; Research grant / Funding (institution): Amgen. U. Keilholz: Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony: Bristol-Myers Squibb; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Merck; Advisory / Consultancy: Serono; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: AstraZeneca; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: MSD Oncology; Honoraria (self), Advisory / Consultancy, Research grant / Funding (self): Pfizer; Honoraria (self), Speaker Bureau / Expert testimony: Novartis; Honoraria (self), Speaker Bureau / Expert testimony: Glycotope GmbH. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.